KBC Securities - UCB S.A. (UCB) UCB Bimzelx launch tracker

Report

KBC Securities

Thomas Vranken

UCB Bimzelx launch tracker

We introduce a Bimzelx launch tracker tool to keep an eye on the ongoing commercialization of Bimzelx in the US by looking at total prescriptions (TRx). Our latest figure for week 7 points to 251 TRx, impacted by the holiday season. Overall, we see a smooth ramp-up for Bimzelx in its first weeks since launch. € 110 TP and Buy rating reiterated.

15/01/2024 1 EN

Underlying

UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.

See profile

BE0003739530 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

SmartInsider

UCB SA: 1 director

A director at UCB SA bought 674 shares at 138.350EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Free Trial

April 25, 2025 April 25, 2025 1 EN

KBC Securities

US Tariffs Navigating the impact on Benelux equities

Trumps reciprocal tariffs caused a massive blow to equity markets, following a pressured period of escalating trade wars. Retaliatory measures can further heavily damage market confidence, as seen Friday when China announced their 34% tarrif of US goods. International trade policies have never moved this erratic and untransparant, with uncertainty and volatility being the baseline for now. In this report we highlight the key stocks in our coverage relevant to this discussion.

April 8, 2025 April 8, 2025 1 EN

ING Financial Markets

Benelux Morning Notes

Ackermans & van Haaren: Nextensa acquiring the “Proximus Towers” landmark project. Avantium: Called to account. Proximus: Finalizes sale of its old HQ to Nextensa and the development of its new one. UCB: No tariffs on pharmaceutical products, at least for now

April 3, 2025 April 3, 2025 1 EN

Aalberts 1Q25 in line with CSS – outlook uncertain

Over 1Q25 Aalberts' topline came in as expected declining 3.3% in line with the issued 1Q guidance calling for a mid single organic revenue decline. Adjusted EBITA landed at €106m (vs. our €115mE and CSS of € 108mE). Overall EBITA margin of 13.6% (vs. 14% CSS, 14.2% KBCe) was down from 14.2% in 1Q24. Gross margin was said to be at a good level, which based on historical track record should thus hover around our estimated 62-63%. Company is not formally reiterating FY25 guidance issued last February and refers to tariff and trade policy induced market uncertainty. Accumulate maintained on valua...

19h / 16m 19h / 16m 1 EN

Wim Lewi

Wim Lewi

Aedifica Launches a share offer on Cofinimmo after take-out speculation

Aedifica proposed a voluntary conditional exchange offer for all outstanding Cofinimmo shares. They offer 1.16 new Aedifica shares per Cofinimmo share. The offer values each Cofinimmo share at EUR 80.91, representing a 20.8% premium over Cofinimmo's “undisturbed” share price of EUR 67.00. and adjusted for the difference in proposed FY24 gross dividends. The offer is subject to a minimum acceptance threshold of 50%+1, a standstill by Cofinimmo and unconditional merger approval in Belgium, the Netherlands, and Germany, as well as FDI approval in France. The share issuance will need to be approve...

19h / 36m 19h / 36m 1 EN

Hilde Van Boxstael ... (+5)

Hilde Van Boxstael
Kristof Samoy
Michiel Declercq
Thomas Couvreur
Wim Lewi

Morning Notes : AALB NA, AED BB, COLR BB, INGA NA

: AALB NA, AED BB, COLR BB, INGA NA

19h / 47m 19h / 47m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

UCB Bimzelx launch tracker

We are a financial services provider for several types of professional clients, each with distinct needs.

UCB SA: 1 director

US Tariffs Navigating the impact on Benelux equities

Benelux Morning Notes

Aalberts 1Q25 in line with CSS – outlook uncertain

Aedifica Launches a share offer on Cofinimmo after take-out speculation

Morning Notes : AALB NA, AED BB, COLR BB, INGA NA

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe